10th Mar 2014 10:19
LONDON (Alliance News) - Oxford Pharmascience Group PLC Monday said it has begun dosing subjects in the pilot clinical study of its OXP001 400 milligram Ibuprofen treatment.
The company redevelops existing medicines to try and make them better, safer and easier to take and is trying to develop a version of Ibuprofen that has reduced risks of gastrointestinal side effects if used for chronic conditions.
Non steroidal anti-inflammatory drugs like Ibuprofen are one of the most widely used medicines worldwide, but they come with side-effects if used heavily, including ulcers and bleeding.
"The study will provide the data that will allow Oxford Pharmascience to proceed with confidence to late Phase III pivotal trials for its reduced gastric irritation ibuprofen product as well as further potential NSAIDs in our pipeline," Chief Executive Marcelo Bravo said in a statement.
Oxford Pharmascience Group shares were up 2.3% at 4.4 pence Monday morning.
By Steve McGrath; [email protected]; @SteveMcGrath1
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Pharmascience Group